|Bid||84.99 x 100|
|Ask||88.51 x 100|
|Day's Range||86.85 - 88.19|
|52 Week Range||78.42 - 102.49|
|PE Ratio (TTM)||-26.14|
|Earnings Date||Aug 2, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||113.83|
On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell.
Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.